Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
CH | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 9, 23 | -0.83 Increased by 0.00% | 0.31 Decreased by -1.19 K% |
| Nov 11, 22 | -0.56 Increased by +22.22% | -0.56 |
| Aug 18, 22 | -1.18 Decreased by -53.25% | -0.56 Decreased by -197.70% |
| May 5, 22 | -0.97 Decreased by -83.02% | -0.52 Decreased by -166.42% |
| Mar 10, 22 | -0.83 | -0.66 Decreased by -39.03% |
| Nov 4, 21 | -0.72 | -0.72 |
| Aug 5, 21 | -0.77 | -0.65 Decreased by -28.40% |
| May 5, 21 | -0.53 | -0.65 Increased by +28.40% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 500.89 K Increased by +111.14% | -2.43 M Increased by +58.66% | Decreased by -485.68% Increased by +80.42% |
| Dec 31, 22 | 592.43 K Increased by +49.04% | -3.82 M Increased by +13.78% | Decreased by -645.20% Increased by +42.15% |
| Sep 30, 22 | 409.42 K Decreased by -39.97% | -4.05 M Decreased by -12.51% | Decreased by -988.79% Decreased by -87.42% |
| Jun 30, 22 | 183.35 K Decreased by -81.53% | -7.35 M Decreased by -56.72% | Decreased by -4.01 K% Decreased by -748.40% |
| Mar 31, 22 | 237.24 K Decreased by -71.90% | -5.88 M Decreased by -122.94% | Decreased by -2.48 K% Decreased by -693.36% |
| Dec 31, 21 | 397.49 K Decreased by -78.17% | -4.43 M Decreased by -108.64% | Decreased by -1.12 K% Decreased by -855.66% |
| Sep 30, 21 | 682.00 K Increased by +2.40 K% | -3.60 M Decreased by -8.61% | Decreased by -527.59% Increased by +95.66% |
| Jun 30, 21 | 992.60 K Increased by +15.31% | -4.69 M Decreased by -50.58% | Decreased by -472.51% Decreased by -30.58% |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.